Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 7/2018

01.07.2018 | Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

Sulfonamide Drug Allergy

verfasst von: Joshua M. Dorn, Mollie Alpern, Caitlin McNulty, Gerald W. Volcheck

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We sought to review past and current literature on sulfonamide drug allergy and distill it in a practical manner to assist the clinician, specifically focusing on cross-reactivity and desensitization.

Recent Findings

There do not appear to be consistent genetic markers to reliably predict features of or the presence hypersensitivity reactions. Recent evidence continues to alleviate early concerns cross-reactivity between sulfonamide antibiotics and non-antibiotics.

Summary

Sulfonamide drug allergy is frequently encountered by the practicing clinician. For sulfonamide antibiotics, delayed rash is the most common clinical manifestation. There is no current evidence to support avoidance of all non-antibiotic sulfonamides in those with a reported allergy to sulfonamide antibiotics, although certain scenarios require caution. Available evidence supports the cautious reintroduction of sulfonamide antibiotics via desensitization, which is usually well tolerated and should be considered in those with strong indications for trimethoprim-sulfamethoxazole and a reported sulfonamide allergy.
Literatur
1.
Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from the Boston collaborative drug surveillance program on 15 438 consecutive inpatients, 1975 to 1982.
2.
Macy E, Poon K-YT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;
3.
McConeghy KW, Caffrey AR, Morrill HJ, Trivedi AN, LaPlante KL. Are non-allergic drug reactions commonly documented as medication “allergies”? A national cohort of veterans’ admissions from 2000 to 2014. Pharmacoepidemiol Drug Saf. 2017;26:472–6.CrossRefPubMed
4.
Anon. Co-trimoxazole and blood. Lancet. Lancet 1973;2:950.
5.
Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients (review). Cochrane Database Syst Rev. 2014:1–67.
6.
Brackett CC, Harleen S, Likelihood BJ. Mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24:856–70.CrossRefPubMed
7.
Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Heal Pharm. 2013;70:1483–94.CrossRef
8.
9.
Ghimire S, Kyung E, Lee JH, Kim JW, Kang W, Kim E. An evidence-based approach for providing cautionary recommendations to sulfonamide-allergic patients and determining cross-reactivity among sulfonamide-containing medications. J Clin Pharm Ther. 2013;38:196–202.CrossRefPubMed
10.
Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother. 2005;39:290–301.CrossRefPubMed
11.
Verdel BM, Souverain PC, Egberts ACG, Leufkens HGM. Difference in risks of allergic reactions to sulfonamide drugs based on chemical structure. Ann Pharmacother. 2006;40:1040–6.CrossRefPubMed
12.
Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Advers drug react. Toxicol Rev. 1996;15:9–50.
13.
Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE. Mol Immunol. 1988;25:1347–54.CrossRefPubMed
14.
Pichler WJ, Adam J, Watkins S, Wuillemin N, Yun J, Drug Hypersensitivity YD. How drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immunol. 2015;168:13–24.CrossRefPubMed
15.
Reilly TP, Mechanistic JC. Perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol. 2002;2:307–15.CrossRefPubMed
16.
Wang D, Curtis A, Papp AC, Koletar SL, Para MF. Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. Biomed Cent Med. Genomics. 2012;5:1–9.CrossRef
17.
• Reinhart JM, Motsinger-Reif A, Dickey A, Yale S, Trepanier LA. Genome-wide association study in immunocompetent patients with delayed hypersensitivity to sulfonamide antimicrobials. PLoS One. 2016;11:1–15. No convincing genetic risk factors found in this population with sulfonamide hypersensitivity.
18.
Sacco J, Abouraya M, Motsinger-Reif A, Yale S, McCarty C, Trepanier L. Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenet Genomics. 2012;22:733–40.CrossRefPubMedPubMedCentral
19.
Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25:402–11.CrossRefPubMed
20.
Zalewska-Janowska A, Spiewak R, Kowalski ML. Cutaneous manifestation of drug allergy and hypersensitivity. Immunol Allergy Clin N Am. 2017;37:165–81.CrossRef
21.
Bӧhm R, Cascorbi I. Pharmacogenetics and predictive testing of drug hypersensitivity reactions. Front Pharmacol. 2016;7:1–11.CrossRef
22.
Muraro A, Lemanske RF, Castells M, Torres MJ, Khan D, Simon HU, et al. Precision medicine in allergic disease—food allergy, drug allergy, and anaphylaxis—PRACTALL document of the European academy of allergy and clinical immunology and the American Academy of Allergy, Asthma and Immunology. Allergy Eur. J Allergy Clin Immunol. 2017;72:1006–21.CrossRef
23.
Weiss ME, Bernstein DI, Blessing-moore J, Cox L, Lang DM, Nicklas RA, et al. Drug allergy: an updated practice parameter. Ann allergy, asthma Immunol. Ann. Allergy Asthma Immunol; 2010;105. 259–273:e78.
24.
Kuyucu S, Mori F, Atanaskovic-Markovic M, Caubet JC, Terreehorst I, Gomes E, et al. Hypersensitivity reactions to non-betalactam antibiotics in children: an extensive review. Pediatr Allergy Immunol. 2014;25:534–43.PubMed
25.
Sharma V, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents—a 6 year series from Chandigarh. India J Postgr Med. 2001;47:95–9.
26.
Hansbrough JR, Wedner J, Chaplin DD. Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol. 1987;80:538–41.CrossRefPubMed
27.
Slatore CG, Tilles SA. Sulfonamide Hypersensitivity. Immunol Allergy Clin N Am. 2004;24:477–90.CrossRef
28.
Author S, Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim. Source J Infect Dis [Internet]. 1988;158:474–7.CrossRef
29.
Moreno Escobosa M, Granados SC, Quesada MM, Lopez JA. Enanthema and Fixed drug eruption caused by trimethoprim. J Investig Allergol Clin Immunol. 2009;19:237–52.
30.
Bonfanti P, Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. Biomed Pharmacother. 2000;54:45–9.CrossRefPubMed
31.
Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood. 1994;84:176–83.PubMed
32.
George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematol Am Soc Hematol Educ Progr. 2009:153–8.
33.
Sanofi-Aventis. LASIX (furosemide). sanofi-aventis,US LLC. 2011;1–11.
34.
Dibbern DA, Montanaro A. Allergies to sulfonamide antibiotics, Allergy s-c d A. Asthma Immunol. American College of Allergy. Asthma & Immunology. 2008;100:91–101.CrossRef
35.
Lin D, Tucker MJ, Rieder MJ. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother. 2006;
36.
Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;
37.
Roujeau J-C, Kelly J, Luigi N, Berthold R, Stern R. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.CrossRefPubMed
38.
Wright AA, Vesta KS, Stark JE, Smith WJ. Stevens-Johnson syndrome associated with furosemide: a case report. J Pharm Pract. 2010;23:367–70.CrossRefPubMed
39.
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80.CrossRefPubMed
40.
Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17
41.
Anliker MD, Wüthrich B. Acute generalized exanthematous pustulosis due to sulfamethoxazol with positive lymphocyte transformation test (LTT). J Investig Allergol Clin Immunol. 2003;13:66–8.PubMed
42.
Lloyd-Lavery A, Chi C-C, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use. JAMA Dermatology. 2013;149:58.CrossRefPubMed
43.
Kidon MI, See Y, Kidon MI. Adverse drug reactions in Singaporean children. Singap Med J. 2004;45
44.
Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from the Boston collaborative drug surveillance program on 15 438 consecutive inpatients, 1975 to 1982. JAMA J Am Med Assoc. 1986;256:3358–63.CrossRef
45.
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;
46.
47.
Gompels MM, Simpson N, Snow M, Spickett G, Ong E. Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Inf Secur. 1999;38:111–5.
48.
49.
Kalish RS, LaPorte A, Wood JAJK. Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions. J Allergy Clin Immunol. 1994;Sep:465–72.CrossRef
50.
Neuman MG, Malkiewicz IM, Phillips EJ, Rachlis AR, Ong D, Yeung E, et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit. 2002;24:728–36.CrossRefPubMed
51.
Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for pneumocystis carinii prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184:992–7.CrossRefPubMed
52.
Shakoor MT, Ayub S, Ayub Z. Sulfa allergy: cross-reactivity versus multiple concurrent allergies. Am J Infect Dis. 2013;9:148–54.CrossRef
53.
Castrejon JL, Berry N, El-Ghaiesh S, Gerber B, Pichler WJ, Park BK, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol. 2010;125:411–8.CrossRefPubMed
54.
Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51:57–62.CrossRefPubMed
55.
Wenyang Fu L, Vender RB. Sulfa or sulfur? Clearing things up. J of cutaneous medicine and. Surgery. 2013;17:79–81.
56.
57.
Dibbern DA, Montanaro A. Allergies to sulfonamide antibiotics and sulfur-containing drugs. Ann Allergy Asthma Immunol. 2008;100:91–101.CrossRefPubMed
58.
Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy SCE, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628–35.CrossRefPubMed
59.
Hemstreet BA, Sulfonamide Allergies PRL. Outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy. 2006;26:551–7.CrossRefPubMed
60.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenic in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentral
61.
Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis. 2002;Jun:66–74.CrossRef
62.
Hughes WT. Use of dapsone in the prevention and treatment of pneumocystis carinii pneumonia: a review. Clin Infect Dis. 1998;27:191–204.CrossRefPubMed
63.
Stern A, Green H, Paul M, Vidal L, Leibovici L, Stern A, et al. Prophylaxis for pneumocystis pneumonia ( PCP ) in non-HIV immunocompromised patients (review). Cochrane Database Syst Rev. 2015:2014–6.
64.
Scherer K, Brockow K, Aberer W, Gooi JHC, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions—an EAACI position paper of the drug allergy interest group. Allergy Eur. J Allergy Clin Immunol. 2013;68:844–52.CrossRef
65.
Demoly P, Messaad D, Sahla H, Fabre J, Faucherre V, André P, et al. Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients. J Allergy Clin Immunol. 1998;102:1033–6.
66.
•• Lin D, Wk L, Mj R. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV / AIDS in patients with previous history of hypersensitivity to cotrimoxazole ( review ). Cochrane database Syst rev. 2007;CD005646 Systematic review of small trials in HIV patients showing desensitization of TMP-SMX resulted in fewer treatment discontinuations and reactions than did direct re-challenge.
67.
•• Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JTC, et al. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract. 2014;2:52–8. Larger series showing high rates of successful desenzitiation to TMP-SMX in those with previously reported sulfonamide adverse drug reactions. CrossRefPubMed
68.
Hughes T, Almgren J, McGuffin R, Omoto R. Co-trimoxazole desensitization in bone marrow transplantation. Ann Intern Med. 1986;Jul:148.
69.
Soffritti S, Ricci G, Prete A, Rondelli R, Menna G, Pession A. Successful desensitization to trimethoprim-sulfamethoxazole after allogeneic haematopoietic stem cell transplantation: preliminary observations. Med Pediatr Oncol. 2003;Apr:271–2.CrossRef
70.
Mann R, Badesch D, Zamora M, Dreskin S. Desensitization to trimethoprim-sulfamethoxazole following lung transplantation. Chest. 1997;111:1147.CrossRefPubMed
71.
Neuman MG, Shear NH, Malkiewicz IM, Kessas M, Lee AW, Cohen L. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol. 2008;17:1045–51.CrossRefPubMed
72.
Alim N, Patel JY. Rapid oral desensitization to furosemide. Ann Allergy Asthma Immunol. 2009;103:538.CrossRefPubMed
73.
Wall GC, Bigner D, Craig S. Ethacrynic Acid and the sulfa-sensitive patient. Arch Intern Med. 2003;163:116–7.CrossRefPubMed
74.
Phipatanakul W, Adkinson NF Jr. Cross-reactivity between sulfonamides and loop or thiazide diuretics: is it a theoretical or actual risk? Allergy Clin Immunol Int [Internet]. 2000;12:26–8.CrossRef
75.
Lee AG, Anderson R, Kardon RH, Wall M. Presumed sulfa allergy in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol. 2004;138:114–8.CrossRefPubMed
76.
Mineo MC, Cheng EY. Severe allergic reaction to hydrochlorothiazide mimicking septic shock. Pharmacotherapy. 2009;29:357–61.CrossRefPubMed
77.
Mark Ruscin J, Page RL, Scott J. Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature. Am J Geriatr Pharmacother. 2006;4:325–9.CrossRefPubMed
78.
De Barrio M, Tornero P, Zubeldia J, Sierra Z, Matheu V, Herrero T. Fixed drug eruption induced by indapamide. Cross-reactivity with sulfonamides. J Investig Allergol Clin Immunol. 1998;8:253–5.PubMed
79.
Gales BJ, Gales MA. Erythema multiforme and angioedema with indapamide and sertraline. Am J Hosp Pharm. 1994;51:118–9.PubMed
80.
Partanen J, Pohjola-Sintonen S, Makijarvi M. Toxic Epidermal Necrolysis due to Indapamide. Arch Dermatol. 1993;129:793.
81.
Stricker BH, Biriell C. Skin reactions and fever with indapamide. Br Med J (Clin Res Ed). 1987;295:1313–4.CrossRef
82.
Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. Int Arch Allergy Immunol. 2010;153:152–6.CrossRefPubMed
83.
Buijs BS, Van Den Berk GE, Boateng CP, Hoepelman AI, Van Maarseveen EM, Arends JE. Cross-reactivity between darunavir and trimethoprim- sulfamethoxazole in HIV-infected patients. AIDS. 2015;29:785–91.CrossRefPubMed
84.
85.
Peralta J. Anaphylactic shock and death after oral intake of acetazolamide. Am J Ophthalmol. 1992;114:367–7.
86.
Tzanakis N, Metzidaki G, Thermos K, Spyraki CH, Bouros D. Anaphylactic shock after a single oral intake of acetazolamide. Br J Ophthalmol [Internet]. 1998;82:588.
87.
Gharib A, Khokhar A, Caperton C V., Hamadani ST. Desensitization to acetazolamide in a patient with previous antimicrobial sulfonamide allergy. Ann Allergy, Asthma Immunol [Internet]. American College of Allergy, Asthma & Immunology; 2017;118:369–70. Available from: https://​doi.​org/​10.​1016/​j.​anai.​2016.​11.​029
88.
Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol 212AD. 69:527–9.
89.
Guedes GB, Karan A, Mayer HR, Shields MB. Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. J Ocul Pharmacol Ther. 2013;29:456–61.CrossRefPubMed
90.
Holtzer CD, Flaherty JFJ, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998;18:831–5.PubMed
91.
Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med. 1996;100:611–6.CrossRefPubMed
92.
Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS. 1993;7:355–9.CrossRefPubMed
93.
• May SM, Motosue MS, Park MA. Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance. J Allergy Clin Immunol Pract. 2017;5:831–3. There is unlikely to be cross-reactivity between TMP-SMX and Dapsone in the HIV population. CrossRefPubMed
94.
Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with pneumocystis carinii pneumonia and AIDS. J Infect Dis [Internet] 1993;167:180–185. Available from: http://​www.​jstor.​org/​stable/​30112589
95.
Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992;5:341–7.PubMed
96.
Glasser DL, Pharm D, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmcotherapy. 2003;23:551–3.CrossRef
97.
Figueroa J, Ortega N, Almeida L, Blanco C, Castillo R. Sulfonamide allergy without cross-reactivity to celecoxib. Allergy Eur. J Allergy Clin Immunol. 2007;
98.
Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf. 2003;26:187–95.CrossRefPubMed
99.
Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther. 1999;
100.
Newman LC, Lay CL, O’Connor KA, Russell M. Lack of cross-reactivity to sumatriptan in patients allergic to sulfonamides: a retrospective chart review (abstract). Headache. 1999;5:372.
101.
Bellón T, Lerma V, González-Valle O, González Herrada C, De Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol. 2016;174:621–4.CrossRefPubMed
102.
Sinha R, Larkin J, Gore M, Fearfield L. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Br J Dermatol. 2015;173:1024–31.CrossRefPubMed
103.
Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172:239–43.CrossRefPubMed
104.
Fisher A. Systemic contact dermatitis from Orinase and Diabinese in diabetics with Para-amino hypersensitivity. Curr Contact News. 1982;29:551.
105.
Bukhalo M, Zeitouni NC, Cheney RT. Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. Cutis. 2003;71:235–8.PubMed
106.
107.
Ritter FJ, Gustafson MC, Karney V, Penovich PE, Moriarty GL, Frost MD, et al. Do allergic reactions to sulfonamide antibiotics predict allergy to zonisamide? Epilepsia. 2002;43:209.
Metadaten
Titel
Sulfonamide Drug Allergy
verfasst von
Joshua M. Dorn
Mollie Alpern
Caitlin McNulty
Gerald W. Volcheck
Publikationsdatum
01.07.2018
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 7/2018
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-018-0791-9

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise